Journal article icon

Journal article

Progress and new frontiers in biomarkers for amyotrophic lateral sclerosis

Abstract:

The adult-onset neurodegenerative disorder amyotrophic lateral sclerosis (ALS) is life-shortening for majority of those affected. Therapeutic trials relying on traditional endpoints such as tracheostomy-free survival, or significant reduction in the slope of decline of the revised ALS Functional Rating Score (ALSFRS-R), entail costly studies which last up to 18 months. Rapid advances in the understanding of the molecular biology of ALS are making the prospect of disease-modifying therapy i...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.2217/bmm-2018-0149

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Clinical Neurosciences
Role:
Author
ORCID:
0000-0003-0267-3180
Publisher:
Future Medicine Publisher's website
Journal:
Biomarkers in Medicine Journal website
Volume:
12
Issue:
7
Pages:
693-696
Publication date:
2018-06-01
Acceptance date:
2018-05-18
DOI:
EISSN:
1752-0371
ISSN:
1752-0363
Pubs id:
pubs:856277
URN:
uri:42b53360-e76b-4237-a174-95806c2df3a4
UUID:
uuid:42b53360-e76b-4237-a174-95806c2df3a4
Local pid:
pubs:856277

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP